Search research articles
Contact Us
Filters
Showing results (251-260 of 311) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F List, Zhuoxin Sun, Amit Verma, et al.
Leukemia & Lymphoma
|
June 3, 2020
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation
Craig W Freyer, Alison Carulli, Alex Ganetsky, et al.
Leukemia & Lymphoma
|
March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
Molly E Graveno, Alison Carulli, Craig W Freyer, et al.
Communications Sustainability
|
February 12, 2026
Riparian vegetation reduces coastal turbidity
Hilary D Brumberg, Laura E Dee, Hikari Murayama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
Donald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Blood Advances
|
May 8, 2026
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)
Wellington F Silva, Jun Yin, Michaela Liedtke, et al.
JCI Insight
|
July 23, 2016
A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Marlise R Luskin, Phyllis A Gimotty, Catherine Smith, et al.
American Journal of Hematology
|
April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents
Gee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2015
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning
Ran Reshef, Austin P Huffman, Amy Gao, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Page
of 32
Search research articles
Search
Showing results (251-260 of 311) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F List, Zhuoxin Sun, Amit Verma, et al.
Leukemia & Lymphoma
|
June 3, 2020
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation
Craig W Freyer, Alison Carulli, Alex Ganetsky, et al.
Leukemia & Lymphoma
|
March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
Molly E Graveno, Alison Carulli, Craig W Freyer, et al.
Communications Sustainability
|
February 12, 2026
Riparian vegetation reduces coastal turbidity
Hilary D Brumberg, Laura E Dee, Hikari Murayama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia
Donald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Blood Advances
|
May 8, 2026
Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)
Wellington F Silva, Jun Yin, Michaela Liedtke, et al.
JCI Insight
|
July 23, 2016
A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Marlise R Luskin, Phyllis A Gimotty, Catherine Smith, et al.
American Journal of Hematology
|
April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents
Gee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 10, 2015
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning
Ran Reshef, Austin P Huffman, Amy Gao, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Page
of 32